Page last updated: 2024-12-07

spinasterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

spinasterol: RN given refers to alpha-spinasterol ((3beta,5alpha,22E)-isomer) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281331
CHEMBL ID487783
CHEBI ID10333
SCHEMBL ID232490
MeSH IDM0098474

Synonyms (47)

Synonym
24r-ethyl-5alpha-cholesta-7,22e-dien-3beta-ol
LMST01040126
stigmasta-7,22e-dien-3beta-ol
17-[(e)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
C08840
481-18-5
spinasterol
alpha-spinasterin
bessisterol
stigmasta-7,22-dien-3-ol, (3-beta,5-alpha,22e)-
hitodesterol
(3-beta,5-alpha,22e)-stigmasta-7,22-dien-3-ol
5-alpha-stigmasta-7,22-dien-3-beta-ol, (e)-
5-alpha-stigmasta-7,22-diene-3beta-ol
bdbm50275507
chebi:10333 ,
CHEMBL487783 ,
(3s,5s,9r,10s,13r,14r,17r)-17-[(e,2r,5s)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
unii-0lg993qx1a
0lg993qx1a ,
.alpha.-spinasterol
stigmasta-7,22-dien-3-ol, (3-.beta.,5-.alpha.,22e)-
5.alpha.-stigmasta-7,22-dien-3.beta.-ol
5-.alpha.-stigmasta-7,22-dien-3-.beta.-ol, (e)-
(3-.beta.,5-.alpha.,22e)-stigmasta-7,22-dien-3-ol
.alpha.-spinasterol [mi]
.alpha.-spinasterin
.delta.7,22-stigmastan-3.beta.-ol
SCHEMBL232490
(3?,5?,22e)-stigmasta-7.22-dien-3-ol
?-spinasterol
stigmasta-7,22-dien-3-ol, (3b,5a,22e)-
(3s,5s,9r,10s,13r,14r,17r)-17-((2r,5s,e)-5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol
AKOS024458312
a-spinasterol
7,22,5alpha-cholestadien-24beta-ethyl-3beta-ol
HY-N6962
F20840
Q15269695
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2-(1h-tetazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylicacid(5-methyl-2-oxo-1,3-dioxol-4-yl)methylester
CS-0028716
MS-27135
spinosterol
(3beta,5alpha,22e)-stigmasta-7,22-dien-3-ol
DTXSID801044364
5alpha-stigmasta-7,22-dien-3beta-ol
delta7,22-stigmastan-3beta-ol

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In time-kill analyses, at concentrations above the MICs, ceftiofur in combination with α-spinasterol exhibited time-dependency and concentration-dependency comparing to time dependency with ceftiofur alone."( A novel method for synthesis of α-spinasterol and its antibacterial activities in combination with ceftiofur.
Cai, Y; Chen, H; Dong, Q; Li, Y; Rong, Q; Shi, F; Tang, H; Wang, T; Xu, M; Yang, X; Ye, G; Zhao, L; Zhou, J; Zhou, X, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"7% at a dosage of 100 mg/kg mouse."( Antigenotoxic spinasterol from Cucurbita maxima flowers.
Bremner, JB; Lemon, P; Palileo, A; Villaseñor, IM, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)30.00000.00041.877310.0000AID654333
Nitric oxide synthase, inducibleMus musculus (house mouse)IC50 (µMol)50.00000.00103.39119.6000AID344829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID344829Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
New diterpenoids and the bioactivity of Erythrophleum fordii.
AID1617255Cytotoxicity against nutrient-rich DMEM cultured human PANC1 cells at PC50 incubated for 24 hrs by WST-8 assay
AID654332Inhibition of advanced glycation end-products formation after 14 days by spectrofluorimetry2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Chemical constituents from the aerial parts of Aster koraiensis with protein glycation and aldose reductase inhibitory activities.
AID1617250Anti-austerity activity against nutrient-deprived human PANC1 cells assessed as cell death incubated for 24 hrs by WST-8 assay
AID344828Inhibition of NADPH oxidase in LPS-induced mouse BV2 cells assessed as NOX-dependent ROS production at 50 uM2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
New diterpenoids and the bioactivity of Erythrophleum fordii.
AID654333Inhibition of Sprague-Dawley rat lens aldose reductase2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Chemical constituents from the aerial parts of Aster koraiensis with protein glycation and aldose reductase inhibitory activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (10.94)18.7374
1990's8 (12.50)18.2507
2000's15 (23.44)29.6817
2010's31 (48.44)24.3611
2020's3 (4.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]